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Abstract 
There is a growing need for biomarkers which predict age-onset pathology. Although this 
is challenging, the methylome offers significant potential. Cancer is associated with the 
hypermethylation of many gene promoters, among which are developmental genes. 
Evolutionary theory suggests developmental genes arbitrate early-late life trade-offs, 
causing epimutations that increase disease vulnerability. Such genes could predict age 
related disease. The aim of this work was to optimise an electrochemical procedure for the 
future investigation of a broad range of ageing related pathologies. An electrochemical 
approach, which adopted three analytical techniques, was used to investigate DNA 
methylation in the EN1 gene promoter. Using synthetic single stranded DNA, one 
technique was able to detect DNA at concentrations as low as 10nM, with methylation 
status distinguishable at concentrations >25nM. A negative correlation could be observed 
between % methylation of heterogeneous solution and the key electrochemical 
parameter, Rct (r = -0.982, p < 0.01). The technique was applied to the breast cancer cell 
line MCF-7, where a similar correlation was observed (r = -0.965, p < 0.01). These results 
suggest electrochemistry can effectively measure DNA methylation at low concentrations 




 Ageing, age-related disease, biomarker, electrochemistry, DNA methylation, cancer 
 
Abbreviations 
AD, Alzheimer’s disease, Au-RDE, gold rotating disk electrode; CAD, coronary artery disease; CpG, 
cytosine-phosphate-guanine; ctDNA, circulating tumour DNA; CV, cyclic voltammetry; CVD, 
cardiovascular disease; EIS, electrochemical impedance spectroscopy; EN1, engrailed-1; DPV, 
differential pulse voltammetry; MCF-7, Michigan Cancer Foundation-7; PBS, phosphate-buffered 
saline Rct, charge transfer resistance; T2DM, type 2 diabetes mellitus, WGA, whole genome 




Ageing is a complex biological phenomenon which is characterised by a decline in physical function 
(1). This physical deterioration results in an increased risk of a multitude of age related diseases, such 
as cardiovascular disease (CVD), Alzheimer’s disease (AD) and cancer (2). These diseases place a 
significant burden on the wellbeing of older people. As an example of this morbidity, almost half of 
American adults (48%) currently live with CVD (3). Moreover, from a global perspective, 60% of all 
cancer cases, and 70% of cancer-related deaths occurs in older people (those ≥ 65 years) (4). Based 
on this evidence it is cogent that appropriate biomedical tools are developed to help diagnose and 
predict age associated diseases so the health-span of older people can be extended. Due to its dense 
tapestry, which involves a multitude of perturbations at the molecular, biochemical and cellular level, 
it is not straightforward to select a biomarker of aging which can be reliably used to predict age related 
disease, with a high degree of accuracy in humans (5, 6). However, experimental and computational 
evidence in the last decade has strongly suggested that DNA methylation changes can act as a 
powerful marker of ageing (7-12). Specifically, advancing age is often accompanied by global 
hypomethylation, as outlined by Barciszewska et al. (2007) who used a TLC-based detection method 
to examine global age-related hypomethylation in human skin fibroblasts (13). Global 
hypomethylation is observed in conjunction with site-specific hypermethylation at the promoter 
region of a variety of genes, which have been ubiquitously associated with age-related disease (14). 
Among the genes whose methylation profile can change with age are developmental genes. The 
aberrant methylation of developmental genes has regularly been associated with disease (15, 16). 
Given that aging can be defined from an evolutionary point of view as the decline in the force of 
natural selection with age (17-19), it is natural to infer that alterations to DNA methylation patterns 
among developmental genes is the consequence of an early-late life trade-off. This line of thinking 
aligns with the mutation accumulation (18) or antagonistic pleiotropy theory of ageing (19), and offers 
the possibility that methylation changes at developmental genes could in part mediate the effects of 
deleterious age-specific epimutations which increase our susceptibility to disease over time, as these 
mutations gradually accumulate in the genome. It is also worth noting that the disposable soma  
theory (DST) (20), which is a physiological version of the antagonistic pleiotropy theory is based on the 
assumption that there is a trade-off between reproductive investment and somatic maintenance 
could also account for age related DNA methylation changes in gene promoters.   
 
 
Based on our evolutionarily logic it is clear age-related methylation changes to developmental genes 
could have the potential to act as a predictor of age-related disease. There are many developmental 
genes which could be investigated for their predictive capabilities, however due to its strong 
association with cancer, the engrailed-1 (EN1) gene is an excellent candidate. The EN1 gene plays an 
important role in pattern formation during embryonic development. First identified in Drosophilia, 
mutations to the homeobox gene have been associated with abnormal development; specifically, 
posterior-anterior duplications and wing malformations. In mice, the En1 gene has been associated 
with limb innervation (21), and cerebellum patterning, with En1-null mice failing to form a cerebellum 
and incurring perinatal death (22). The human ortholog EN1 has been associated with central nervous 
system pattern formation, with expression observed in the midgestational medulla and cerebellum 
(23). Despite this gene playing a vital role during embryonic development, EN1 has been associated 
with the development of cancer later in life, through changes to the methylation patterns within the 
gene promoter. Hypermethylation of the EN1 promoter has been associated with a reduced gene 
expression in colorectal (24), prostate (25), and lung cancer (26). Additionally, several studies have 
correlated EN1 gene hypermethylation with tumour size/grading and mortality (27, 28). Moreover, 
the importance of EN1 has been underscored due to its role in protecting mesencephalic 
dopaminergic neurons from oxidative stress, in a mouse model of Parkinson’s disease (29). Thus, these 
genes are important to ageing and the methylation of the EN1 gene promoter offers a potential 
biomarker for prediction of age-associated conditions, and in particular cancer.  
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The aim of this work is to use the EN1 promoter as a model for quantifying methylation. To do this 
there a number of traditional experimental techniques which could be adopted. These include 
bisulphite sequencing, methylation specific PCR, and microarray analysis (30, 31). Unfortunately, 
these techniques are time consuming and expensive, and do not make ideal platforms for the future 
development of biosensors which are capable of rapidly, efficiently and cheaply predicting the onset 
of age related disease. In contrast, electrochemical methods help to overcome these challenges, and 
in recent years have been successfully used to quantify gene promoter methylation (32-34). Most 
notably, the utility of this approach with the EN1 promoter has been underscored by the work of Koo 
and colleagues who in recent years introduced the eMethylsorb method (35-37). This procedure 
involves adsorbing bisulphite treated and asymmetrically amplified DNA onto a gold electrode before 
submerging the electrode into Fe2+/Fe3+ redox solution, within a three-electrode redox cell, and 
conducting differential pulse voltammetry (DPV). Bisulphite treatment converts unmethylated 
cytosines to uracil, while methylated cytosines remain unchanged (38). Asymmetric PCR then 
produces single stranded DNA rich in either adenine or guanine (39). As nucleotides bind to gold with 
the following affinities: A > C ≥ G >T (40), treated unmethylated samples passivate the surface to a 
greater degree than methylated samples. This is then observed as a differential electrochemical signal. 
Using this principle, synthetic 30 base ssDNA, designed to represent methylated and unmethylated 
variants of a region downstream of the transcription start site of the EN1 gene promoter, that have 
undergone bisulphite treatment and asymmetric amplification, will be adsorbed to a rotating gold disk 
electrode (Au-RDE). Electrochemical impedance spectroscopy (EIS), and cyclic voltammetry (CV) 
measurements will be taken, in addition to DPV. After optimisation, the procedure will be applied to 
bisulphite treated and asymmetrically amplified DNA extracted from the breast cancer cell line MCF-
7.  
 
2. Materials and Methods 
 
2.1 Synthetic Oligonucleotides 
Synthetic oligonucleotides were used to represent methylated and unmethylated variants of a region 
downstream of the transcription start site, of the EN1 gene promoter, which had undergone bisulphite 
treatment and asymmetric amplification (Table 1). The oligonucleotides were 30 bases in length, and 
contained six CpG sites (Eurofins Genomics). Samples were diluted to 50nM in 1X PBS (137mM sodium 
chloride, 2mM potassium chloride, 10mM phosphate buffer, pH 7.4, amresco, E404-200TABS) for the 
optimisation of adsorption time and rotation speed. To examine the effect of concentration, a range 
of 0-400nM was employed. Following this test, 200nM solutions were used to detect % methylation. 
Solutions were stored at 4ᵒC for 1 month, and were tested at room temperature. 
 
 














2.2 Cell Culturing 
MCF-7 Cells (gifted from, and grown at, Chester Medical School, University of Chester) were cultured 
in Eagle's Minimum Essential Medium (Lonza, LZBE12-611F) supplemented with 10% foetal bovine 
serum (Invitrogen Gibco, Fisher, 11573397) and 1% non-essential amino acids (SLS, M7145), and 
incubated at 37°C at 5% CO2. Cells were trypsinised at 70% confluence for DNA extraction.   
 
2.3 DNA Extraction and Preparation 
DNA was extracted from MCF-7 cells using QIAGEN QIAamp® DNA Mini Kit (50) (QIAGEN, 51304) 
according to the manufacturer’s instructions. Extracted DNA was stored at -20ᵒC. After dilution in 
nuclease free water (USB Corporation, 71786), the concentration of DNA was calculated as 
739.8µg/ml using a Varioskann Lux fluorescent plate reader (Thermo scientific), using equation: 
Concentration (µg/ml) = (A260 – A320) × dilution factor × 50µg/ml 
Purity was calculated as 1.763 via the equation: 
DNA purity = A260/A280 
Whole genome DNA (Roche Diagnostics GmbH, 11691112001) was diluted in nuclease free water to 
a concentration of 50ng/µl and amplified using the whole genome amplification kit - REPLI-g UltraFast 
Mini kit (QIAGEN, 150033) according to the manufacturer’s instructions. It was estimated a 
concentration of 500ng/µl was created. The MCF-7 DNA and whole genome amplified (WGA) DNA 
then underwent bisulphite modification using the MethylEasy Xceed kit (Human Genetic Signatures, 
ME002) according to the manufacturer’s instructions, to produce 20ng/µl bisulphite modified DNA. 
The bisulphite modified DNA was stored at -20°C. 
 
2.4 Asymmetric PCR and Amplification Verification  
Asymmetric PCR was utilised to generate ssDNA of a section the EN1 gene promoter from MCF-7 and 
WGA DNA. For the first round of PCR, 2µl of 20ng/µl MCF-7 or WGA DNA was combined with 12.5µl 
2X PCR master mix (BIO-RAD, 1662119), 6.5µl nuclease free water, 3µl of 10µM forward primer, and 
1µl of 1µM reverse primer (Eurofins Genomic, 30:1 primer ratio). For the second round of PCR, 2µl of 
PCR product was combined with 12.5µl 2X PCR master mix, 4.5µl nuclease free water, 5µl 10µM 
forward primer and 1µl 1µM reverse primer. Primer ratio for second round PCR was 50:1 as outlined 
in Table 2 (39). The thermocycler was programmed for predenaturation at 95°C for 3 minutes, before 
a 30 cycle program of denaturation at 95°C for 1 minute, annealation at 50°C for 2 minutes, and 
extension at 72°C for 2 minutes. Final extension followed for 10 minutes at 72°C. Programming was 







Table 2. Asymmetric PCR forward and reverse primers. 
 
To verify amplification, gel electrophoresis was conducted on 2% agarose gel containing 1X GelRed 
nucleic acid stain (Biotium, 41003-1) in 1X TAE buffer (BIO-RAD, 166-0742). Samples were prepared 
by combining 10µl of Orange G loading buffer (BIO-RAD, 1662119) with 25µl of secondary PCR product 
before 10µl of sample was added to each loading well. Gel electrophoresis was run at 100V for 90 
minutes, and images were taken using UVP BioDoc-It 220 Imaging system M-20V Transilluminator and 
Doc-It LS image analysis software (Version 8.6).  
For electrochemical testing, 600µl (1/3), 100µl (1/18), 50µl (1/36) and 10µl (1/180) of secondary PCR 
product were combined with 1X PBS to make an overall volume of 1.8ml. A dilution of 1/18 was used 
to test % methylation in heterogeneous samples of MCF-7 and WGA DNA (0, 25, 50, 75 and 100%). 
 
2.5 Electrochemical Testing 
The redox cell consisted of: 2mm gold rotating disk electrode (Au-RDE, Radiometer analytical, BM-
EDI101), Ag/AgCl reference electrode (ALS, RE1CP), 0.127mm diameter coiled platinum counter 
electrode (Alfa Aesar, 00263), in ~70ml of 2.5mM Fe2+/2.5mM Fe3+/1X PBS redox solution (Potassium 
hexacyanoferrate (II) trihydrate, AnalaR NORMAPUR, 26816.298, and potassium hexacyanoferrate 
(III), AnalaR NORMPUR, 26810.232) containing a magnetic stirring bar. The redox cell was placed on a 
plastic topped magnetic stirring platform (HANNA Instruments, HI-190M), and electrodes were 
attached to the potentiostat (Princeton applied research, BiStat). The potentiostat was controlled via 
the software EC-Lab V11.10. 
Before each adsorption step, the Au-RDE electrode was polished using figure of eight motions for 30 
seconds on silk (Kemet, 341752) with 6µm diamond spray, on silk with 3µm diamond spray (Kemet, 
116004), and on felt (Kemet, 341208) with a saturated 1µm alumina solution (Kemet, 600253). 
Between each step, the electrode was rinsed in ultrapure water and dried. Following this 3 step 
polishing process, the electrode was sonicated in ultrapure water for 30 seconds, and dried. Following 
polishing, DNA samples were adsorbed onto the Au-RDE at an appropriate rotation speed for an 
appropriate time, before insertion into the redox cell. The redox solution was mixed for 10 seconds 
before each EIS, CV and DPV measurement was taken (Figure 1). 
EIS was conducted at open circuit potential, at a scanning frequency between 200 kHz and 100mHz, 
with 10 points per decade and a voltage amplitude of 20mV. A Z-fit analysis was conducted within EC-
Lab V11.10, using the equivalent circuit selection R1+Q2/(R2+W2) to gain parameter values for R2. R2 
was subsequently referred to as Rct. CV was performed at open circuit potential with a scan speed of 
200mV/s up to a vertex potential of 0.8V and backwards to -0.15V vs. Ag/AgCl with a potential step of 
1mV, and Peak to peak separation. From the cyclic voltammogram, ΔEp (mV), was determined. DPV 
Primer 5’-Sequence-3’ 
Concentration (µM) 









Reverse  ACRACCRCAACAACCAAACCCT 0.04 0.04 
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was performed by scanning the potential between -0.2 and 0.7V vs. Ag/AgCl with a potential step of 
5mV, a pulse amplitude of 50mV, a pulse width of 50ms, and a pulse period of 100ms (41). Peak anodic 
current, ipa (µA) recorded from the differential pulse voltammogram. Results recorded as mean ± 1 
standard deviation. RSD, also known as the coefficient of variance, was also reported. Correlations 
were evaluated using a Pearsons correlation analysis on SPSS Version 25. To undertake multiple 
comparisons analyses, a one-way ANOVA with a Tukey Post Hoc test was conducted. 
 







3.1.1 Synthetic Oligonucleotides 
The first variable to be optimised was DNA adsorption time (Figure 2A). A DNA adsorption time of 1 
minute was sufficient to bring about a statistically significant increase in Rct, when compared to 0 
minutes (p<0.05). However, it was not until 30 minutes that Rct was distinguishable between 50nM 
methylated and unmethylated samples (p<0.05). The second variable optimised was rotation speed 
(Figure 2B). Z-fit analysis of electrochemical impedance spectra revealed the greatest difference in Rct 
between 50nM methylated and unmethylated samples was at a rotation speed of 2000rpm, with a 
difference of 321.43Ω between means. Moreover, the Rct for 50nM methylated and unmethylated 
DNA samples were exclusively statistically different at a rotation speed of 2000rpm (p<0.05). 
Electrochemical impedance spectra and data can be observed in the supplementary results file, 
Appendix A. The third parameter to be optimised was DNA concentration (Figure 2C). The limit of 
detection was 10nM for both methylated and unmethylated DNA, as determined by a one-way ANOVA 
with a Tukey post-hoc test. Importantly, methylation status was not distinguishable until >25nM 
(p<0.05). However, the greatest difference between methylated and unmethylated DNA solutions was 
observed at 200nM. Therefore 200nM was determined as the optimum concentration to determine 
DNA methylation, and was the concentration of choice to detect % methylation in a heterogeneous 
sample of methylated and unmethylated DNA (Figure 2D). A strong negative correlation between % 
methylation and Rct was observed (r = -0.982, p < 0.01). Additionally, all solutions tested produced 
statistically distinguishable Rct values (p<0.05), except for 25 vs. 50% (p>0.05). 
3.1.2 MCF-7 and WGA DNA 
The volume of test solution was reduced to 1.8ml to account for the low quantities of secondary PCR 
product. A ratio of 1/3 was selected firstly as this was the ratio utilised by Koo and colleagues (35). 
Further dilutions of 1/18, 1/36, and 1/180 were also tested to determine the limit of detection for the 
experimental technique (Figure 2E). It was established only 10µl of secondary PCR product in 1.8ml 1X 
PBS (1/180) was required to detect the presence of MCF-7 and WGA DNA statistically (p<0.05). 
However, it was not possible to statistically distinguish the EN1 gene promoter amplicon from MCF-7 
and WGA DNA until 100µl of secondary PCR product was used in 1.8ml 1X PBS (1/18). This was also 
the ratio where the greatest difference in Rct between MCF-7 and WGA DNA was observed. Therefore, 
this ratio was used to test for % methylation in heterogeneous solution (Figure 2F). As with the 
synthetic oligonucleotides, a negative correlation was observed between % methylation and Rct (r = -
0.965, p < 0.01), however the effect of percentage methylation was more pronounced. Furthermore, 
the Rct values for 0, 25, 50, 75, and 100% methylated solutions adsorbed onto the 2mm Au-RDE for 5 
minutes at 2000rpm were all statistically different from one another when statistically analysed with 





Figure 2. Influence of DNA methylation on Rct. 
Rct determined through Z fit analysis of Nyquist plots for a 2mm Au-RDE in 2.5mM 
ferrocyanide/2.5mM ferricyanide/1X PBS after adsorption of ssDNA. Optimisation of A) adsorption 
time of 50nM ssDNA at a rotation speed of 2000rpm, B) rotation speed of Au-RDE for adsorption of 
50nM ssDNA for 5 minutes, and C) oligonucleotide concentration adsorbed at 2000rpm for 5 minutes. 
D) Depicts the correlation between % methylation of heterogeneous samples of 200nM synthetic 
oligonucleotides adsorbed on to the Au-RDE for 5 minutes at 200rpm, and Rct. Pearsons’ linear 
correlation coefficient r, and p are displayed on plot. E) Optimisation of amount of secondary PCR 
product, derived from bisulphite treated MCF-7 and WGA DNA, in 1.8ml of 1X PBS, adsorbed onto Au-
RDE for 5 minutes at 2000rpm. Results correspond to 1/180, 1/36, 1/18 and 1/3 dilutions. F) Depicts 
the correlation between % methylation of heterogeneous samples of 1/18 MCF-7 (methylated) and 
WGA (unmethylated) DNA adsorbed on to Au-RDE for 5 minutes at 2000rpm, and Rct. Pearsons’ linear 
correlation coefficient r, and p are displayed on plot. * indicates p<0.05 between methylated and 







3.2.1 Synthetic Oligonucleotides 
Increased adsorption time resulted in an increase in ∆𝐸𝑝 for 50nM methylated DNA, unmethylated 
DNA, and 1X PBS (Figure 3A). Cyclic voltammograms and data can be found in Appendix A. ∆𝐸𝑝 for 
50nM methylated and unmethylated DNA was statistically distinguishable at adsorption times of 5, 
15, 20, 25, and 30 minutes, at a rotation speed of 2000rpm (p<0.05). Increased rotation speed resulted 
in a general elevation in ∆𝐸𝑝 (Figure 3B). As with the results from the analysis of Rct, a statistically 
significant difference was only observed for ∆𝐸𝑝 at 2000rpm for 50nM methylated and unmethylated 
DNA solutions adsorbed onto the 2mm Au-RDE for 5 minutes (p<0.05). ∆𝐸𝑝 also rose as DNA 
concentration increased (Figure 3C). The limit of detection was identified as 10nM for methylated and 
25nM for unmethylated DNA (p<0.05). However, DNA solutions were not statistically distinguishable 
from one another until >25nM, and again, the greatest difference between DNA samples was 
observed at 200nM. As outlined in Figure 3D, ∆𝐸𝑝 was negatively correlated with % methylation in a 
heterogeneous solution of 200nM synthetic DNA (r = -0.807, p < 0.01). Cyclic voltammetry was a less 
effective tool for distinguishing % methylation in a heterogeneous sample, as ∆𝐸𝑝 for only 0, 25 and 
50% solutions were statistically different against 100% methylation (p<0.05), while all other 
comparisons did not reach statistical significance. 
 
3.2.2 MCF-7 and WGA DNA 
∆𝐸𝑝 generally increased as the amount of secondary PCR product in 1X PBS increased (Figure 3E). The 
limit of detection was established as >50µl of secondary PCR product in 1.8ml 1X PBS (1/36, p<0.05). 
Furthermore, at this level, MCF-7 and WGA amplicons were statistically distinguishable (p<0.05). 
However, the greatest difference between ∆𝐸𝑝 values for MCF-7 and WGA DNA was at 100µl 
secondary PCR product used in 1X PBS (1/18). Therefore, this ratio was used to examine % methylation 
(Figure 3F). A negative correlation between % methylation in heterogeneous solution, and ∆𝐸𝑝 was 
observed (r = -0.964, p < 0.01). Again, the effect of % methylation on ∆𝐸𝑝 was more pronounced for 
MCF-7 and WGA DNA when compared with synthetic oligonucleotides. ∆𝐸𝑝 was less effective at 
differentiating % methylation for heterogeneous solutions of MCF-7 and WGA DNA, than Rct, as ∆𝐸𝑝 




Figure 3. Influence of DNA methylation on ΔEp. 
ΔEp determined through analysis of cyclic voltammograms for a 2mm Au-RDE in 2.5mM 
ferrocyanide/2.5mM ferricyanide/1X PBS after adsorption of ssDNA. Optimisation of A) adsorption 
time of 50nM ssDNA at a rotation speed of 2000rpm, B) rotation speed of Au-RDE for adsorption of 
50nM ssDNA for 5 minutes, and C) oligonucleotide concentration adsorbed at 2000rpm for 5 minutes. 
D) Depicts the correlation between % methylation of heterogeneous samples of 200nM synthetic 
oligonucleotides adsorbed on to the Au-RDE for 5 minutes at 200rpm, and ΔEp. Pearsons’ linear 
correlation coefficient r, and p are displayed on plot. E) Optimisation of amount of secondary PCR 
product, derived from bisulphite modified MCF-7 and WGA DNA, in 1.8ml of 1X PBS, adsorbed onto 
Au-RDE for 5 minutes at 2000rpm. Results correspond to 1/180, 1/36, 1/18 and 1/3 dilutions. F) 
Depicts the correlation between % methylation of heterogeneous samples of 1/18 MCF-7 
(methylated) and WGA (unmethylated) DNA adsorbed on to Au-RDE for 5 minutes at 2000rpm, and 
ΔEp. Pearsons’ linear correlation coefficient r, and p are displayed on plot. * indicates p<0.05 between 






3.3.1 Synthetic Oligonucleotides 
𝑖𝑝𝑎 declined as adsorption time increased. The richer adenine content of the unmethylated DNA 
sample resulted in a lower 𝑖𝑝𝑎 than its methylated counterpart, while the adsorption of 1X PBS onto 
the 2mm Au-RDE led to a substantially greater 𝑖𝑝𝑎 (Figure 4A). Further to this, 𝑖𝑝𝑎 was greatest when 
no immersion occurred. This can be observed in the differential pulse votammograms and data in the 
supplementary results file. A statistically significant difference was observed between the 𝑖𝑝𝑎 gained 
for 50nM methylated and unmethylated DNA adsorbed onto the 2mm Au-RDE for 5, 20 and 30 
minutes (p<0.05). An adsorption time of 5 minutes was selected to conduct further experimentation 
at, as it was the minimum time required for a statistical difference to be observed between 50nM 
methylated and unmethylated DNA samples (∆𝐸𝑝 and 𝑖𝑝𝑎). Next, rotation speed was optimised (Figure 
4B), where it was established that a statistical difference was only observed at a rotation speed of 
2000rpm (p<0.05). Following this, concentration was examined (Figure 4C). As the concentration of 
both methylated and unmethylated DNA increased, there was a subsequent reduction in 𝑖𝑝𝑎. 
Interestingly the limit of detection for methylated DNA was 1nM, although 10nM of unmethylated 
DNA was required to produce a statistically significant difference from 0nM (p<0.05). However, >50nM 
was required to differentiate methylated and unmethylated DNA solutions (p<0.05). Using the 
optimised variables of, adsorption of 200nM DNA for 5 minutes at 2000rpm, a strong positive 
correlation between % methylation and  𝑖𝑝𝑎 was observed (r = 0.902, p < 0.01) (Figure 4D). 𝑖𝑝𝑎 was 
more effective than cyclic voltammetry in differentiating methylation status, as only 0% vs. 25% and 
50% vs. 75% solutions could not be distinguished, while all other comparisons reached statistical 
significance (p<0.05). 
3.3.2 MCF-7 and WGA DNA 
A decrease in 𝑖𝑝𝑎 was typically observed as the amount of secondary PCR product in 1.8ml 1X PBS 
increased (Figure 4E). Remarkably 10µl of MCF-7 or WGA DNA in 1.8ml was sufficient to bring about 
a statistical difference when compared to 1X PBS. However, 50-100µl (1/36-1/18) of secondary PCR 
product in 1.8ml 1X PBS was required to differentiate the two amplicons using DPV (p<0.05). The 
greatest difference was observed for 1/18 solutions, where 𝑖𝑝𝑎 for MCF-7 DNA was 21.94±0.53µA 
compared with 13.90 ±0.18µA for WGA DNA. Using this concentration, a strong positive correlation 
between 𝑖𝑝𝑎 and % methylation in a heterogeneous solution was observed (r = 0.856, p < 0.01), and 
again the effect was more pronounced (Figure 4F). For instance, when using MCF-7 and WGA DNA, 
𝑖𝑝𝑎 ranged between 13.90 ±0.18 and 21.94 ±0.53 for 0-100% methylation, whereas using synthetic 
oligonucleotides produced results ranging from 18.34 ±0.58 to 20.89 ±0.30. Despite this increase in 
range, 0% vs. 25%, 0% vs. 50%, and 25% vs. 50% were not statistically different when analysed using 




Figure 4. Influence of DNA methylation on ipa. 
ipa determined through analysis of differential pulse voltammograms for a 2mm Au-RDE in 2.5mM 
ferrocyanide/2.5mM ferricyanide/1X PBS after adsorption of ssDNA. Optimisation of A) adsorption 
time of 50nM ssDNA at a rotation speed of 2000rpm, B) rotation speed of Au-RDE for adsorption of 
50nM ssDNA for 5 minutes, and C) oligonucleotide concentration adsorbed at 2000rpm for 5 minutes. 
D) Depicts the correlation between % methylation of heterogeneous samples of 200nM synthetic 
oligonucleotides adsorbed on to the Au-RDE for 5 minutes at 200rpm, and ipa. Pearsons’ linear 
correlation coefficient r, and p are displayed on plot. E) Optimisation of amount of secondary PCR 
product, derived from bisulphite treated MCF-7 and WGA DNA, in 1.8ml of 1X PBS, adsorbed onto Au-
RDE for 5 minutes at 2000rpm. Results correspond to 1/180, 1/36, 1/18 and 1/3 dilutions. F) Depicts 
the correlation between % methylation of heterogeneous samples of 1/18 MCF-7 (methylated) and 
WGA (unmethylated) DNA adsorbed on to Au-RDE for 5 minutes at 2000rpm, and ipa. Pearsons’ linear 
correlation coefficient r, and p are displayed on plot. * indicates p<0.05 between methylated and 






4. Discussion  
The world population is ageing. With an ageing population there comes a commensurate increase in 
the prevalence of age related disease. Age related diseases such as CVD and cancer compromise 
human healthspan and place a significant burden on the wellbeing of older people. It is imperative 
biomarkers are identified which are capable of predicting age related disease. It is conceivable that 
promoter specific age related gene methylation changes are capable of predicting the onset of age 
related disease; while electrochemical techniques provide the necessary foundations for translating 
this approach into a diagnostic tool. In this work we have demonstrated that this simple 
electrochemical procedure can detect DNA methylation in both homogenous and heterogeneous 
samples of synthetic ssDNA and breast cancer cell line MCF-7 DNA. Specifically, analysis of 30 base 
synthetic DNA, designed to represent a methylated and unmethylated bisulphite modified and 
asymmetrically amplified section of the EN1 gene promoter revealed DNA methylation could be 
detected by EIS, CV and DPV. Greater Rct (EIS) and ∆Ep (CV), and lower ipa (DPV) were observed for 
unmethylated samples, demonstrating its higher affinity for the Au-RDE, and thus greater passivation 
of the Au-RDE, than its methylated counterpart. Rct (EIS) was the most effective electrochemical 
parameter (method) for the detection of DNA methylation in heterogeneous solutions of synthetic 
DNA, when the optimum procedure (200nM DNA for 5 minutes at 2000rpm) was employed; followed 
by ipa (DPV), and ∆Ep (CV). Similarly, Sina et al. (2014) reported 200nM was the optimum DNA 
concentration for creating greatest current difference between samples. Although Koo et al. (2014) 
reported that a concentration of 50nM was optimum, this may be because a 53 base sequence 
containing eight CpG sites was used, in comparison to the 30 base sequence containing six CpG sites 
utilised in this work. Another difference is that the technique outlined in this work resulted in a 50% 
reduction in adsorption time, compared to that reported by both Sina et al. (2014) and Koo et al. 
(2014). This could be explained by the use of a rotating gold electrode in comparison to a non-motile 
electrode. While one-time use Au-SPE, as used by Koo et al. (2014), have benefits such as a low cost, 
ability to change their design and are disposable, their inability to rotate could lead to reduced 
adsorption. Additionally, it is important to consider that although the Au-RDE requires polishing 
between tests, while the Au-SPE does not require cleaning due to its disposable nature, the polishing 
procedure outlined in this study took approximately 3 minutes to complete. Therefore, this electrode 
processing time totalled 8 minutes, 20% less time than required for the disposable Au-SPR. However, 
it is important to note that this does not include the sample processing time, which incorporates DNA 
extraction, bisulphite treatment, and asymmetric PCR.  
This work  provided an insight into the potential of this technique for determining DNA methylation 
in human derived samples. For this, the procedure was optimised to 1/18 secondary PCR product in 
1X PBS for MFC-7 and WGA DNA. These results again indicated Rct was superior at detecting DNA 
methylation in heterogeneous samples compared with ∆Ep, and ipa. It is vital the sensor is able to 
detect % methylation in heterogeneous samples, as cancerous masses often exhibit intratumour 
heterogeneity (42). It is also important to consider the implications that a technique such as this, may 
have in detection and monitoring of tumours through a non-invasive blood test, rather than through 
the more invasive traditional biopsy. Tumour DNA is often released into circulation as cell free 
fragments of DNA, and this circulating tumour DNA (ctDNA) has been suggested as a potential 
biomarker for cancer (43). Previously ctDNA has been detected in >75% of patients with metastatic 
cancers, including, but not limited to, bladder, ovarian, breast, colorectal, and hepatocellular cancer 
(44). Additionally, a correlation between the number of cancer patients with detectable levels of 
ctDNA and cancer stage was reported; ctDNA was detected in 47% of patients with stage 1 cancer, 
55% of patients with stage 2 cancer, 69% of patients with stage 3 cancer, and 82% of patients with 
stage 4 cancer. Furthermore, the amount of detectable ctDNA was positively correlated with grade, 
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and negatively correlated with two year survival rate (44). Therefore, this technology could be used 
to indicate disease severity and prognosis, in addition to determining the presence of the disease. 
The low levels of DNA required by the technique outlined in this paper could be a factor in deciding 
which method to use to detect DNA methylation. This is because many techniques require larger 
concentrations of DNA, which could limit their applicability in some instances. For example, ELISA 
based kits require >100ng DNA, while the DNA restriction digest based technique LUMA requires 250-
500ng DNA (45). Based on previous work which has reported circulating DNA in cancer patients to be 
on average 219ng/ml (range 10-1200ng/ml) while control individuals exhibited <2ng/ml (46),the 
developed sensor should be sensitive enough to detect the presence of cancer given the collection of 
a 5ml blood sample. However, it is important to recognise the importance of the investigations which 
used methylation specific PCR to determine ctDNA methylation, as a biosensor for lung cancer (47). 
Results show ≥1 out of 5 genes analysed exhibited aberrant methylation in 77% of lung biopsies from 
patients, whereas the same result was only observed in 49.5% of samples derived from serum (47). 
Similar findings were reported by in a further study which found only 44% of serum samples from 
cancer patients exhibited hypermethylation of the CDKN2A gene promoter. Therefore, it is important 
to consider that these so called liquid biopsies may have reduced sensitivities than traditional biopsies. 
In this work, electrochemical techniques were used to detect methylation in breast cancer cells, 
however it is vital to realise that this technology could be applied to alterative gene promoters for the 
detection of cancer, such as BRCA1 for breast cancer (48). Furthermore, it is important to recognise 
the potential of this technology if it were applied to commonly methylated gene promoters from a 
larger scope of age-related disease; such as the INS gene promoter in type 2 diabetes mellitus (T2DM) 
(49), the OPRD1 gene promoter in AD (50), the SLC6A4 gene promoter in obesity (51), or the ABCA1 
gene promoter in coronary artery disease (CAD) (52), which have all been shown to be 
hypermethylated during disease. Moreover, this technology could be used to estimate age itself. This 
is a logical assumption to make, as Horvaths epigenetic clock describes the methylation trend of 353 
CpG sites with age, and has an accuracy of 3.6 years. Within this model, methylation of 193 CpG sites 
positively correlate with age, and 160 CpG sites negatively correlate with age. Given further 
optimisation of the electrochemical procedure outlined, it may be possible to use these methods to 
determine epigenetic age (7).  
Moreover, the technique could be refined and improved to investigate the pleiotropic effects 
methylation can have on genes during different stages of life. There are many developmental genes 
which are regulated by DNA methylation to allow tissue specific expression and expression at different 
times of development, with aberrant methylation resulting in disease (15). In this work we specifically 
refer to EN1, a key homeobox gene, in which aberrant DNA methylation is associated with perturbed 
gene expression and cancer. For instance, hypermethylation of the EN1 gene in a region far upstream 
of the promoter was positively correlated with gene expression in invasive breast cancer (53). 
Interestingly, reduced levels of methylation within the EN1 gene promoter have been associated with 
increased expression of EN1 in in basal-like breast tumours (54). Overexpression of EN1 has been 
observed to behave as a pro-survival transcription factor in basal-like breast cancer (55). Clinical work 
has revealed patients with basal-like breast cancer tended to be younger at menarche, have increased 
parity, and a younger age at first full-term pregnancy (56). This evidence provides a clear link between 
DNA methylation and subsequent perturbation of EN1 expression and cancer pathogenesis, with 
health in females of post-reproductive age. Therefore, the EN1 gene could be suggested as an example 
gene which supports the antagonistic pleiotropy theory of ageing. For instance, it is unambiguous the 
wild-type EN1 gene would be selected for, as mutations result in dramatic mutations or death. 
However, various studies have reported that changes to the DNA methylation patterns within the 
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gene promoter in later life are associated with cancer. Therefore, the susceptibility of the homeobox 
gene to aberrant DNA methylation in later life is a trade-off with the beneficial effects of the gene 
during embryonic development. It is possible therefore that DNA methylation may be a key regulator 
of the deleterious effects of genes in later life, confer an advantage pre-reproduction. 
 
4.1. Limitations of this Work  
It is imperative to consider how this technique could be refined and developed in the future. A 
limitation of the technique used in this investigation is that the samples underwent bisulfite 
treatment. Recently, progress has been made in the development of electrochemical biosensors (57-
60). These electrochemical bioplatforms determine with high sensitivity and selectivity 5-mC and 5-
hmC both at global and gene-specific levels using synthetic oligonucleotides. In this instance, assay 
times ranged between 45 and 90 minutes, and crucially are performed without using bisulfite 
treatment or amplification as a precursor. It is important that advances such as these are embraced, 
and will lead to the future refinement of this approach.    
 
5. Conclusion 
Electrochemical techniques may be a useful tool for detecting changes in DNA methylation patterns, 
which can be associated with disease such as cancer. Furthermore, techniques such as these may be 
able to provide insights into tumour size, grading and mortality. This work revealed Rct derived from 
EIS was superior at detecting DNA methylation in heterogeneous samples compared with ∆𝐸𝑝 from 
CV, and 𝑖𝑝𝑎 derived from DPV. This inexpensive and rapid means of testing DNA methylation, was able 
to detect DNA methylation in heterogeneous samples of both synthetic and human-derived DNA. 
Detecting percent methylation in a heterogeneous sample is important as often intratumour 
heterogeneity is often observed within cancerous masses. Furthermore, we describe that it may be 
possible for future advances in this technology to diagnose cancer through a non-invasive liquid blood 
test due to the release of ctDNA into blood. We also highlight the potential of this test for the detection 
of other age related diseases such as AD, CAD, and T2DM, where aberrant methylation is observed. 
Moreover the technique could be used to investigate the pleiotropic effects of genes throughout life. 
Finally we highlight how this technique will be refined and developed further in the near future by 
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